Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Nephrology

Staying on Track: Monitoring and Daily Life

At a Glance

Long-term dRTA care focuses on keeping bicarbonate and potassium balanced, checking kidney function and stone risk, and adjusting alkali safely. Children may also need growth and hearing monitoring, while illness requires a clinician-approved sick-day plan.

Living with distal renal tubular acidosis (dRTA) requires a shift from “treating a crisis” to “managing a lifestyle.” Because dRTA is often a long-term condition, the goal of ongoing care is to maintain a steady chemical balance that protects your kidneys, bones, and overall health. This involves a partnership with your nephrology team to monitor key lab markers and adjust your treatment safely as your body changes over time [1][2].

Your Monitoring Checklist

While every care plan is unique, standard management typically involves an individualized “surveillance schedule” to ensure your treatment is hitting its targets.

1. Blood and Urine Labs

In the beginning, or after a change in your medication dose, labs are checked frequently. Once your levels are stable, they are usually checked several times a year based on your clinician’s recommendation [3].

  • Serum Bicarbonate: The primary marker of success. The goal is to reach an individualized, “near-normal” target set by your clinician [1][3].
  • Potassium and eGFR: These track your muscle/heart safety and your overall kidney filtering strength [4][5].
  • Urinary Calcium and Citrate: These are vital markers for assessing stone risk. While they do not directly prove your blood is actively acidotic, high calcium and low citrate in the urine are signs that your risk of kidney stones remains elevated and treatment or hydration may need adjustment [6][5].
  • Growth Tracking (for children): A child’s growth curve is a sensitive indicator of whether their dRTA is well-controlled. Steady growth suggests the internal environment is healthy [6][7].

2. Imaging and Specialist Referrals

  • Renal Ultrasound: Ultrasounds are used when clinically indicated to monitor for nephrocalcinosis (calcium deposits) and kidney stones [2][7].
  • Hearing Tests (Audiometry): For inherited forms of dRTA (especially those involving the ATP6V1B1, ATP6V0A4, or FOXI1 genes), regular hearing checks are essential [8][9]. Because hearing loss can appear later in childhood or be progressive, a normal “newborn screen” does not mean monitoring should stop [8][10].
  • Bone Density (DXA) Scans: Adults with dRTA or children with persistent bone pain or fractures may need DXA scans to monitor bone mineral density, though this is ordered based on individual risk rather than as a universal standard [11][12].

Managing the Daily Toll and “Sick Days”

The “work” of dRTA management is significant. Traditional alkali treatments often require multiple doses throughout the day and night, which can be difficult to sustain.

  • Adherence Barriers: The salty or sour taste of some medicines and gastrointestinal (GI) discomfort (like bloating or gas) are common reasons why people struggle to stick to their schedule. Speak with your doctor about alternatives if this is a challenge [13][14].
  • Sick Day Rules: Minor illnesses, vomiting, or diarrhea can quickly change your fluid and acid-base balance. Never double your potassium-based alkali dose to “make up” for a missed pill without direct instruction from your doctor. Ask your care team for a specific “sick day plan” so you know when to seek medical evaluation.

Transitioning from Pediatric to Adult Care

As children with dRTA enter their teenage years, it is time to start planning for the “handover” to adult care. This transition is a gradual process [2][15].

  • Lifelong Care: Because genetic dRTA does not go away, it is critical to find an adult nephrologist who understands rare tubular disorders [2][16].
  • Developing Independence: Adolescents should gradually take over the responsibility for taking their medication, refilling prescriptions, and explaining their condition to others [2].
  • The Handover Record: Ensure your pediatric team provides a comprehensive summary that includes your genetic test results, history of kidney stones, hearing test results, and the specific alkali doses that have worked best for you [2].

By staying consistent with monitoring and medication, you can minimize the long-term impact of dRTA and ensure your kidneys remain as healthy as possible throughout your life [17][7].

Common questions in this guide

What tests are used to monitor distal renal tubular acidosis?
Monitoring usually includes blood bicarbonate, potassium, and estimated kidney filtering (eGFR), along with urine calcium and citrate. Children may also have growth checks, and kidney ultrasound, hearing tests, or bone-density scans are added when the clinical situation calls for them.
How often should dRTA blood and urine tests be done?
Testing is usually more frequent when dRTA is first treated or after the alkali dose changes. Once results are stable, tests are often done several times a year, but your nephrologist should set the schedule for you or your child.
Why are urine calcium and citrate checked in dRTA?
High urine calcium or low urine citrate can mean that the risk of kidney stones remains high. These results do not by themselves prove that blood acidity is currently abnormal, but they can help the care team decide whether treatment or hydration needs adjustment.
Do people with inherited dRTA need hearing tests?
Some inherited forms of dRTA, including those linked to ATP6V1B1, ATP6V0A4, or FOXI1, can cause hearing loss that appears later or worsens over time. A normal newborn hearing screen does not replace ongoing testing, so the nephrology and hearing-care teams should recommend the timing.
What should I do if vomiting or diarrhea affects a dRTA medication dose?
Vomiting and diarrhea can quickly change fluid and acid-base balance, so ask your care team for a written sick-day plan. Do not double a potassium-based alkali dose to make up for a missed dose unless your doctor specifically tells you to, and follow the plan for when to seek medical care.
How can families prepare for the move from pediatric to adult dRTA care?
Genetic dRTA is lifelong, so transition should begin before the handover and include finding an adult nephrologist familiar with tubular disorders. Keep a summary of genetic results, stone history, hearing tests, growth information, and effective alkali doses.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Distal renal tubular acidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my/my child's most recent results, do we need to adjust the alkali dose to get closer to our individualized bicarbonate target?
  2. 2.How often should we be doing urine tests for calcium and citrate to assess stone risk?
  3. 3.Since we have a specific gene mutation, how frequently should we schedule formal hearing tests, even if everything seems fine now?
  4. 4.Do we need an updated sick day plan for how to handle medication doses if vomiting or diarrhea occurs?
  5. 5.For parents: Can we review my child's growth curve together to see if the current treatment is supporting a healthy growth rate?
  6. 6.What is the long-term plan for transitioning my child's care to an adult nephrologist, and what records should we keep for that move?

References

References (17)
  1. 1

    Primary Distal Renal Tubular Acidosis: Toward an Optimal Correction of Metabolic Acidosis.

    Medina E, Ariceta G, Batlle D

    Clinical journal of the American Society of Nephrology : CJASN 2024; (19(9)):1212-1222 doi:10.2215/CJN.0000000000000535.

    PMID: 38967973
  2. 2

    Long-term complications of primary distal renal tubular acidosis.

    Santos F, Gil-Peña H

    Pediatric nephrology (Berlin, Germany) 2023; (38(3)):635-642 doi:10.1007/s00467-022-05546-w.

    PMID: 35543873
  3. 3

    Distal renal tubular acidosis: ERKNet/ESPN clinical practice points.

    Trepiccione F, Walsh SB, Ariceta G, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2021; (36(9)):1585-1596 doi:10.1093/ndt/gfab171.

    PMID: 33914889
  4. 4

    Treatment and long-term outcome in primary distal renal tubular acidosis.

    Lopez-Garcia SC, Emma F, Walsh SB, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2019; (34(6)):981-991 doi:10.1093/ndt/gfy409.

    PMID: 30773598
  5. 5

    Clinical evaluation of Chinese patients with primary distal renal tubular acidosis.

    Zhang C, Ren H, Shen P, et al.

    Internal medicine (Tokyo, Japan) 2015; (54(7)):725-30 doi:10.2169/internalmedicine.54.9421.

    PMID: 25832932
  6. 6

    Improving outcomes for patients with distal renal tubular acidosis: recent advances and challenges ahead.

    Watanabe T

    Pediatric health, medicine and therapeutics 2018; (9()):181-190 doi:10.2147/PHMT.S174459.

    PMID: 30588151
  7. 7

    Clinical and molecular aspects of distal renal tubular acidosis in children.

    Besouw MTP, Bienias M, Walsh P, et al.

    Pediatric nephrology (Berlin, Germany) 2017; (32(6)):987-996 doi:10.1007/s00467-016-3573-4.

    PMID: 28188436
  8. 8

    Hearing Loss Related to Gene Mutations in Distal Renal Tubular Acidosis.

    Ay E, Gurses E, Aslan F, et al.

    Audiology & neuro-otology 2023; (28(5)):350-359 doi:10.1159/000529486.

    PMID: 37121229
  9. 9

    Acidosis and Deafness in Patients with Recessive Mutations in FOXI1.

    Enerbäck S, Nilsson D, Edwards N, et al.

    Journal of the American Society of Nephrology : JASN 2018; (29(3)):1041-1048 doi:10.1681/ASN.2017080840.

    PMID: 29242249
  10. 10

    A novel homozygous deletion in ATP6V0A4 causes distal renal tubular acidosis: A case report.

    Yuan J, Huang K, Wu W, et al.

    Medicine 2019; (98(30)):e16504 doi:10.1097/MD.0000000000016504.

    PMID: 31348261
  11. 11

    Bone microarchitecture using HR-pQCT in adult patients with renal tubular acidosis presenting with rickets/osteomalacia.

    Arjunan D, Mukherjee S, Bhadada SK, et al.

    Archives of osteoporosis 2025; (20(1)):63 doi:10.1007/s11657-025-01545-0.

    PMID: 40358759
  12. 12

    Bone mineral density and growth changes in patients with distal renal tubular acidosis after two-years treatment with a new alkalizing drug (ADV7103).

    Bertholet-Thomas A, Manso-Silván MA, Navas-Serrano V, et al.

    Nefrologia 2023; (43(4)):458-466 doi:10.1016/j.nefroe.2022.02.012.

    PMID: 36529656
  13. 13

    Recent Developments in the Treatment of Pediatric Distal Renal Tubular Acidosis.

    Boyer O, Ould Rabah M, Preka E

    Paediatric drugs 2024; (26(6)):649-657 doi:10.1007/s40272-024-00651-9.

    PMID: 39325135
  14. 14

    Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatments.

    Bertholet-Thomas A, Guittet C, Manso-Silván MA, et al.

    Pediatric nephrology (Berlin, Germany) 2021; (36(1)):83-91 doi:10.1007/s00467-020-04693-2.

    PMID: 32712761
  15. 15

    Young Adults With Hereditary Tubular Diseases: Practical Aspects for Adult-Focused Colleagues.

    Alhasan K, D'Alessandri-Silva C, Mongia A, et al.

    Advances in chronic kidney disease 2022; (29(3)):292-307 doi:10.1053/j.ackd.2021.11.004.

    PMID: 36084976
  16. 16

    Distal renal tubular acidosis: a systematic approach from diagnosis to treatment.

    Giglio S, Montini G, Trepiccione F, et al.

    Journal of nephrology 2021; (34(6)):2073-2083 doi:10.1007/s40620-021-01032-y.

    PMID: 33770395
  17. 17

    6-year treatment follow-up with an extended-release alkaline formulation (Sibnayal®) in primary distal renal tubular acidosis.

    Bertholet-Thomas A, De Mul A, Bernardor J, et al.

    Orphanet journal of rare diseases 2025; (20(1)):431 doi:10.1186/s13023-025-03953-4.

    PMID: 40804680

This page explains monitoring and daily management of distal renal tubular acidosis for informational purposes only and does not constitute medical advice. Do not change alkali doses or illness plans without guidance from your nephrology team.